Allerca Settles on RNA Interference as Key to The Development of Hypoallergenic Housecat | GenomeWeb

Although RNA interference has revolutionized the lifesciences, the technology is still relatively unknown to the general population. All that may change, at least for the average pet lover, if Los Angeles-based Allerca achieves its goal of using the gene-silencing technology to develop a hypoallergenic cat.

According to Simon Brodie, the president of the six-person company, the idea to develop the genetically-modified cat has been around for years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.